Skip to content

Cardiac MR (CMR) in Cardiac Resynchronization Therapy Non-responders

Cardiac MR (CMR) in Cardiac Resynchronization Therapy (CRT) Non-responders: Therapy Optimization by Means of Tissue Characterization, Hemodynamic Analysis and Analysis of Myocardial Activation

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01367691
Enrollment
1
Registered
2011-06-07
Start date
2011-06-30
Completion date
2013-12-31
Last updated
2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

CRT, heart failure, CMR, safety

Brief summary

Cardiac MR (CMR) will be used to assess myocardial activation and hemodynamics in patients with CRT. Goals are to demonstrate that * differences in Left ventricle (LV)- right ventricle (RV) pacing delays cause differences in myocardial activation * differences in LV-RV pacing delays cause differences in LV/RV hemodynamics and to use these data to optimize CRT.

Detailed description

CMR will be performed in patients under CRT who are currently not responding to CRT. Different LV-RV delays will be programmed during CMR and LV function and different dyssynchrony parameters will be assessed. Results will be used to determine the optimal LV-RV delay, and CRT-devices will be reprogrammed accordingly. Improvement in NYHA-class/conversion to therapy responder will be determined clinically after 3 months.

Interventions

DEVICECRT reprogramming (Medtronic CRT)

CRT devices will be reprogrammed according to CMR analysis

Sponsors

University Hospital, Bonn
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* presence of CRT device * CRT non responder

Exclusion criteria

* pregnancy * end-stage renal failure

Design outcomes

Primary

MeasureTime frame
improvement in NYHA-class6 months

Secondary

MeasureTime frameDescription
safety of CMR in CRT-patients6 monthspacing capture threshold, sensing and lead impedances will be monitored for significant and/or clinically relevant changes.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026